Diagnosis and Management of Tuberculosis

Diagnostic Approach

The European Respiratory Society recommends that all persons with cough lasting 2 weeks or more should be evaluated for TB, along with those presenting with unexplained chronic fever and/or weight loss 1, 2
The Centers for Disease Control and Prevention suggests that sputum smear microscopy, specifically Auramine-O staining, is more sensitive and less time-consuming than conventional Ziehl-Neelsen staining, and remains a cornerstone in high-burden settings despite lower sensitivity 3, 4, 5
The World Health Organization recommends that mycobacterial culture is the gold standard for diagnosis, essential for drug susceptibility testing and diagnosing smear-negative TB 1, 2

The American Thoracic Society recommends that all new TB patients should receive a 6-month regimen consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol in the intensive phase, followed by isoniazid and rifampicin in the continuation phase 1, 2, 8
The European Respiratory Society suggests that fixed-dose combinations are highly recommended to improve adherence and simplify treatment 1, 2
The Centers for Disease Control and Prevention recommends that patients should remain in isolation until three consecutive negative sputum smears are collected on different days, and clinical improvement is demonstrated 3, 4, 5

The World Health Organization recommends that HIV-infected patients require expedited diagnostic evaluation and should receive the same first-line regimen as HIV-uninfected patients 1, 2
The American Academy of Pediatrics suggests that children's diagnosis is based on chest radiography consistent with TB, plus either exposure history or positive tuberculin skin test 1, 2
The Infectious Diseases Society of America recommends that extrapulmonary TB diagnosis involves obtaining appropriate specimens from suspected sites for microscopy, culture, and histopathology 1, 2, 7